An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder

Trial Profile

An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs AV 101 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2017 According to a VistaGen Therapeutics media release, the company expects top-line results from the study during the first half of 2018.
    • 13 Feb 2017 According to a VistaGen Therapeutics media release, U.S. National Institute of Mental Health (NIMH) is conducting this trial under VistaGens Cooperative Research and Development Agreement (CRADA) with the NIMH. Company anticipates that the NIMH will complete this study by the end of 2017.
    • 20 Jan 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top